Subretinal delivery of ABBV-RGX-314 gene therapy demonstrated safety and sustained anti-VEGF protein expression at higher doses in patients with neovascular age-related macular degeneration, according to a study.
“Currently, many patients with nAMD require frequent intraocular injections of an anti-VEGF protein to control exudation and maintain vision, and observational studies have shown that many patients do not get the frequency of injections needed and therefore lose vision,” Peter A. Campochiaro, MD, lead author of the study published in The Lancet, told Healio. “Treatments